First reports from CROI: the cure, new drugs, kids, PrEP and hepC

5 April 2012. Related: News.

The Conference of Retroviruses and Opportunistic Infections (CROI) is the most important annual HIV conference.

Our first reports are mow published in HIV Treatment Bulletin (HTB) online and in print.

Exciting and important new breakthroughs including for: cure research, pipeline drug. children’s studies including new formulations, PrEP: close to 100% protection? HIV reinfection and new hepatitis C drugs.

Much of the conference is available as web casts and references in HTB also link to the study abstracts. Further coverage will continue in the next issue, with pre-press articles available online.

CROI reports

• Cure research takes centre stage: proof of concept for activating the latent reservoir

• Quad fixed-dose integrase combination: phase 3 studies at week 48

• Dolutegravir studies continue to show promise

• Tenofovir prodrug: 10 day monotherapy study sets dose at 25 mg for easier coformulation

• Paediatric formulations of ARVs: including an exciting new class

• Lower malaria risk in children receiving lopinavir/ritonavir-based compared to NNRTI-based ART

• High prevalence of d4T-associated lipodystrophy including lipoatrophy in children

• Lopinavir/ritonavir monotherapy in children

• Stopping treatment after early ART in infants

• PrEP: PK modeling of daily TDF/FTC (Truvada) provides close to 100% protection against HIV infection

• Risk of HIV reinfection may be similar to risk of initial HIV infection

• Case report: homozygous CCR5 delta-32 protection overcome by infection with X4 virus

• No association between atazanavir and MI or stroke in D:A:D study

• Hepatitis C coinfection studies

• Herpes Zoster vaccine safe and effective in HIV positive people

• High dose flu vaccine improves antibody responses in HIV positive people

• High dose flu vaccine improves antibody responses in HIV positive people